SCHEMBL3767741

SCHEMBL3767741

O=C(C=Cc1ccc2c(c1)OCO2)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
ALDH1A1 P00352 7/20 0.63
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
MAOB P27338 4/20 0.61
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
TRPV1 Q8NER1 3/20 0.60
HPGD P15428 6/20 0.58
SMN1; SMN2 Q16637 3/20 0.54
CYP3A4 P08684 2/20 0.54
HSD17B10 Q99714 2/20 0.54
GABRA1 P14867 2/20 0.54
GABRB2 P47870 2/20 0.54
LMNA P02545 2/20 0.54
CTSD P07339 1/20 0.54
ABCB1 P08183 1/20 0.54
ALOX5 P09917 1/20 0.54
MAOA P21397 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767737 1.00 KDM4E (0.63) KDM4EALDH1A1KMT2AMEN1MAOB
Cinoxopazide SCHEMBL2107817 0.89 MAOB (0.78) KDM4EALDH1A1KMT2AMEN1MAOB
Cinoxopazide SCHEMBL10520206 0.89 MAOB (0.78) KDM4EALDH1A1KMT2AMEN1MAOB
SCHEMBL3774043 0.83 GPR183 (0.58) NPC1RAB9A
SCHEMBL3774031 0.83 GPR183 (0.58) NPC1RAB9A
SCHEMBL3773930 0.83 KMT2A (0.61) KDM4EALDH1A1KMT2AMEN1NPC1
SCHEMBL3765617 0.82 ALDH1A1 (0.58) ALDH1A1KMT2ALMNAMAPK1TP53
SCHEMBL3767721 0.82 MEN1 (0.56) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL3767727 0.82 MEN1 (0.56) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL3765623 0.82 ALDH1A1 (0.58) ALDH1A1KMT2ALMNAMAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.